218 results on '"Koprich, James B."'
Search Results
2. Enhanced firing of locus coeruleus neurons and SK channel dysfunction are conserved in distinct models of prodromal Parkinson’s disease
3. Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson’s disease mice
4. Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice
5. Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy
6. Modeling with the A53T α-synuclein model of Parkinson's disease
7. Contributors
8. Exosome markers of LRRK2 kinase inhibition
9. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein
10. Brain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson's disease.
11. Generation and Analysis of Viral Vector-Mediated Rodent Models for Parkinson’s Disease
12. Update on Molecular Imaging in Parkinson’s Disease
13. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease
14. Animal models of α-synucleinopathy for Parkinson disease drug development
15. Reply to “Can STN DBS protect both nigral somata and innervation of the striatum?”
16. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson’s Disease
17. Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson’s disease
18. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques
19. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease.
20. Functional Enhancement and Protection of Dopaminergic Terminals by RAB3B Overexpression
21. Reproducibility of A Parkinsonism-Related Metabolic Brain Network in Non-Human Primates: A Descriptive Pilot Study With Fdg Pet
22. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat
23. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset
24. New insights into the organization of the basal ganglia
25. α-Synuclein–induced Kv4 channelopathy in mouse vagal motoneurons drives nonmotor parkinsonian symptoms
26. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque
27. Propagated α-synucleinopathy recapitulates REM sleep behaviour disorder followed by parkinsonian phenotypes in mice
28. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque
29. l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinsonʼs disease
30. MDMA administration to pregnant Sprague–Dawley rats results in its passage to the fetal compartment
31. The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinsonʼs Disease
32. The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson’s Disease
33. Pharmacodynamic Markers of LRRK2 Inhibition in Biofluids
34. α-Synuclein-induced Kv4 channelopathy in mouse vagal motoneurons causes non-motor parkinsonian symptoms
35. Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats
36. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque
37. Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson’s Disease
38. Predictive Markers of LRRK2 Inhibition in Biofluids
39. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease
40. Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease
41. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease
42. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model
43. Corrigendum to “Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism” [Neurobiol. Dis. 106 (2018) 133–146]
44. Non-steric-zipper models for pathogenic α-synuclein conformers
45. Update on Molecular Imaging in Parkinson’s Disease
46. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism
47. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat model
48. Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque
49. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era
50. Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.